Anavex Life Sciences Corp.: may proceed with planned blarcamesine study

What happened Anavex Life Sciences Corp. announced on Oct 15, 2026 that it received notification from the U.S. Food and Drug Administration that the company may proceed with its planned clinical study under its investigational new drug application for blarcamesine in Fragile X syndrome.

Key details

• Notification date: Oct 15, 2026.
• Regulator: U.S. Food and Drug Administration.
• Program: planned clinical study under the company’s investigational new drug application for blarcamesine in Fragile X syndrome.
• The company filed a press release dated Oct 15, 2026 as Exhibit 99.1 to the Form 8-K.

Why it may matter This Form 8-K reports Item 8.01 (Other events), which covers the company’s disclosure that it received FDA notification that it may proceed with the planned clinical study under its investigational new drug application for blarcamesine in Fragile X syndrome. The filing does not show why the company acted.